BioLineRx Ltd. (TLV:BLRX)
Israel · Delayed Price · Currency is ILS · Price in ILA 1.500
-0.100 (-6.25%)
Jun 4, 2026, 11:50 AM IDT
BioLineRx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.4 | 1.18 | 28.94 | 4.8 | - | - | |
Revenue Growth (YoY) | -93.72% | -95.92% | 502.92% | - | - | - |
Cost of Revenue | 0.29 | 0.23 | 9.26 | 3.69 | - | - |
Gross Profit | 1.11 | 0.95 | 19.68 | 1.11 | - | - |
Selling, General & Admin | 3.01 | 3.14 | 29.68 | 31.58 | 11.53 | 5.31 |
Research & Development | 9 | 8.09 | 9.15 | 12.52 | 17.63 | 19.47 |
Operating Expenses | 12.01 | 11.24 | 38.83 | 44.1 | 29.16 | 24.78 |
Operating Income | -10.9 | -10.29 | -19.15 | -42.99 | -29.16 | -24.78 |
Interest Expense | -1.08 | -1.25 | -9.07 | -2.14 | -1.79 | -0.98 |
Interest & Investment Income | 1.12 | 1.12 | 1.82 | 2.01 | 0.69 | 0.28 |
Currency Exchange Gain (Loss) | 0.34 | 0.34 | 0.05 | 0.06 | -0.35 | 0.28 |
Other Non Operating Income (Expenses) | 0.78 | 8.05 | 18.39 | -10.84 | 5.64 | -1.85 |
EBT Excluding Unusual Items | -9.74 | -2.03 | -7.97 | -53.91 | -24.95 | -27.05 |
Asset Writedown | - | - | -1.26 | -6.7 | - | - |
Pretax Income | -9.74 | -2.03 | -9.22 | -60.61 | -24.95 | -27.05 |
Earnings From Continuing Operations | -9.74 | -2.03 | -9.22 | -60.61 | -24.95 | -27.05 |
Minority Interest in Earnings | 1.84 | 0.85 | - | - | - | - |
Net Income | -7.9 | -1.18 | -9.22 | -60.61 | -24.95 | -27.05 |
Net Income to Common | -7.9 | -1.18 | -9.22 | -60.61 | -24.95 | -27.05 |
Shares Outstanding (Basic) | 2,576 | 2,465 | 1,198 | 963 | 774 | 663 |
Shares Outstanding (Diluted) | 2,576 | 2,465 | 1,198 | 963 | 774 | 663 |
Shares Change (YoY) | 73.94% | 105.76% | 24.37% | 24.47% | 16.75% | 162.19% |
EPS (Basic) | -0.00 | -0.00 | -0.01 | -0.06 | -0.03 | -0.04 |
EPS (Diluted) | -0.00 | -0.00 | -0.01 | -0.06 | -0.03 | -0.04 |
Free Cash Flow | -7.79 | -8.1 | -43.93 | -22.72 | -26.37 | -23.67 |
Free Cash Flow Per Share | -0.00 | -0.00 | -0.04 | -0.02 | -0.03 | -0.04 |
Gross Margin | 79.24% | 80.51% | 67.99% | 23.08% | - | - |
Operating Margin | -777.46% | -871.78% | -66.18% | -895.65% | - | - |
Profit Margin | -563.69% | -99.58% | -31.86% | -1262.79% | - | - |
Free Cash Flow Margin | -555.92% | -686.36% | -151.78% | -473.42% | - | - |
EBITDA | -10.75 | -10.06 | -15.16 | -41.61 | -28.5 | -24.07 |
EBITDA Margin | - | - | -52.38% | - | - | - |
D&A For EBITDA | 0.15 | 0.23 | 3.99 | 1.38 | 0.65 | 0.7 |
EBIT | -10.9 | -10.29 | -19.15 | -42.99 | -29.16 | -24.78 |
EBIT Margin | - | - | -66.18% | - | - | - |
Revenue as Reported | 1.18 | 1.18 | 28.94 | 4.8 | - | - |